|
EP3793576A1
|
|
Lysates of recombinant yeast for inducing cellular immune responses
|
|
US2018214525A1
|
|
Modified yeast-brachyury immunotherapeutic compositions
|
|
AU2015243256A1
|
|
Yeast-based immunotherapy and type I interferon sensitivity
|
|
WO2015123532A1
|
|
Ras g12r immunotherapy for ras mutation-positive cancers
|
|
WO2015031778A2
|
|
Compositions and methods for the treatment or prevention of tuberculosis
|
|
AU2014202315A1
|
|
Methods for producing yeast-based vaccines
|
|
TW201834682A
|
|
Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
|
|
CN105228646A
|
|
Based on the chordoma immunotherapy of yeast
|
|
AU2013231199A1
|
|
Yeast-based vaccines as immunotherapy
|
|
US2013344110A1
|
|
Compositions and methods to elicit immune responses against pathogenic organisms using yeast-based vaccines
|
|
AU2013200249A1
|
|
Yeast-based vaccine for inducing an immune response
|
|
AU2012216725A1
|
|
Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
|
|
AU2012296425A1
|
|
Yeast-MUC1 immunotherapeutic compositions and uses thereof
|
|
EP2720716A1
|
|
Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
|
|
NZ724797A
|
|
Yeast-brachyury immunotherapeutic compositions
|
|
MX358496B
|
|
Yeast-based therapeutic for chronic hepatitis b infection.
|
|
SG192285A1
|
|
Yeast-based therapeutic for chronic hepatitis b infection
|
|
EP2651439A2
|
|
Compositions and methods for the treatment or prevention of human adenovirus-36 infection
|
|
AU2011254055A1
|
|
Yeast-based therapeutic for chronic hepatitis C infection
|
|
EP2547792A1
|
|
Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
|
